Literature DB >> 29795766

Synthesis and in Vitro Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists.

An De Prins1,2, Charlotte Martin1, Yannick Van Wanseele2, Csaba Tömböly3, Dirk Tourwé1, Vicky Caveliers4,5, Birgitte Holst6, Ann Van Eeckhaut2, Mette M Rosenkilde6, Ilse Smolders2, Steven Ballet1.   

Abstract

Neuromedin U (NMU) is a multifunctional neuropeptide which is characterized by a high conservation through all species. Herein, we describe the synthesis of a novel set of NMU-analogs based on the truncated NMU-8. Through combination of previously reported modifications, an elaborate structure-activity relationship study was performed aiming for the development of peptides with an increased selectivity toward NMU receptor 1 (NMUR1). Compound 7 possessed the highest NMUR1 selectivity (IC50 = 0.54 nM, selectivity ratio = 5313) together with an increased potency (EC50 = 3.7 nM), an 18% increase of the maximal effect at NMUR1, and a higher resistance against enzymatic degradation as compared to the native NMU-8. The development of a potent NMUR1 agonist with extended half-life could represent an attractive tool to further unveil the role of NMUR1 in NMU signaling.

Entities:  

Year:  2018        PMID: 29795766      PMCID: PMC5949835          DOI: 10.1021/acsmedchemlett.8b00105

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  21 in total

1.  To protect peptide pharmaceuticals against peptidases.

Authors:  R Rink; A Arkema-Meter; I Baudoin; E Post; A Kuipers; S A Nelemans; M Haas Jimoh Akanbi; G N Moll
Journal:  J Pharmacol Toxicol Methods       Date:  2010-02-20       Impact factor: 1.950

2.  Development of potent and proteolytically stable human neuromedin U receptor agonists.

Authors:  An De Prins; Charlotte Martin; Yannick Van Wanseele; Louise Julie Skov; Csaba Tömböly; Dirk Tourwé; Vicky Caveliers; Ann Van Eeckhaut; Birgitte Holst; Mette Marie Rosenkilde; Ilse Smolders; Steven Ballet
Journal:  Eur J Med Chem       Date:  2017-12-14       Impact factor: 6.514

3.  Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake.

Authors:  Louise S Dalbøge; Søren L Pedersen; Søren B van Witteloostuijn; Jakob E Rasmussen; Kristoffer T G Rigbolt; Knud J Jensen; Birgitte Holst; Niels Vrang; Jacob Jelsing
Journal:  J Pept Sci       Date:  2014-12-17       Impact factor: 1.905

4.  A potent neuromedin U receptor 2-selective alkylated peptide.

Authors:  Naoki Nishizawa; Yoko Kanematsu-Yamaki; Masaaki Funata; Hiroaki Nagai; Ayako Shimizu; Hisashi Fujita; Junichi Sakamoto; Shiro Takekawa; Taiji Asami
Journal:  Bioorg Med Chem Lett       Date:  2017-09-09       Impact factor: 2.823

5.  Small lipidated anti-obesity compounds derived from neuromedin U.

Authors:  Ewa D Micewicz; Omar S O Bahattab; Gary B Willars; Alan J Waring; Mohamad Navab; Julian P Whitelegge; William H McBride; Piotr Ruchala
Journal:  Eur J Med Chem       Date:  2015-07-14       Impact factor: 6.514

6.  Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2.

Authors:  Kentaro Takayama; Kenji Mori; Koji Taketa; Akihiro Taguchi; Fumika Yakushiji; Naoto Minamino; Mikiya Miyazato; Kenji Kangawa; Yoshio Hayashi
Journal:  J Med Chem       Date:  2014-07-18       Impact factor: 7.446

7.  Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.

Authors:  Philippe Neuner; Andrea M Peier; Fabio Talamo; Paolo Ingallinella; Armin Lahm; Gaetano Barbato; Annalise Di Marco; Kunal Desai; Karolina Zytko; Ying Qian; Xiaobing Du; Davide Ricci; Edith Monteagudo; Ralph Laufer; Alessandro Pocai; Elisabetta Bianchi; Donald J Marsh; Antonello Pessi
Journal:  J Pept Sci       Date:  2013-11-13       Impact factor: 1.905

8.  Structural versatility of peptides containing C alpha, alpha-dialkylated glycines: conformational energy computations, i.r. absorption and 1H n.m.r. analysis of 1-aminocyclopropane-1-carboxylic acid homopeptides.

Authors:  M Crisma; G M Bonora; C Toniolo; V Barone; E Benedetti; B Di Blasio; V Pavone; C Pedone; A Santini; F Fraternali
Journal:  Int J Biol Macromol       Date:  1989-12       Impact factor: 6.953

Review 9.  Neuromedin U and its receptors: structure, function, and physiological roles.

Authors:  Paul J Brighton; Philip G Szekeres; Gary B Willars
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

10.  The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation.

Authors:  Christoph S N Klose; Tanel Mahlakõiv; Jesper B Moeller; Lucille C Rankin; Anne-Laure Flamar; Hiroki Kabata; Laurel A Monticelli; Saya Moriyama; Gregory Garbès Putzel; Nikolai Rakhilin; Xiling Shen; Evi Kostenis; Gabriele M König; Takashi Senda; Dustin Carpenter; Donna L Farber; David Artis
Journal:  Nature       Date:  2017-09-06       Impact factor: 49.962

View more
  1 in total

1.  Structural insights into the peptide selectivity and activation of human neuromedin U receptors.

Authors:  Chongzhao You; Yumu Zhang; Peiyu Xu; Sijie Huang; Wanchao Yin; H Eric Xu; Yi Jiang
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.